SeaStar Medical Holding Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.1M
- Price
- $3.29
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.30%
- Volume
- 33.1K
About
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Quick stats
Shares outstanding4.0M
Computed float4.0M
Float / shares99.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001831868
AI Summary
AI-generated1/18
majorbullishearnings
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase versus the prior year, driven by sales of its QUELIMMUNE therapy for pediatric acute kidney injury.
The NEUTRALIZE-AKI pivotal trial has enrolled 223 of 339 targeted patients, with completion anticipated by year-end or Q1 2027, positioning the company for a PMA submission near the end of 2027.
The company also obtained ICD-10-PCS codes from CMS to enable standardized inpatient billing for its SCD therapy, effective October 1, 2026.
Red flags
- Cash position decreased from $12.0 million to $7.0 million in six months
- Net loss of $3.7 million for the quarter